Get the Stockscreener App
3.05
1.67%
0.05
After Hours:
3.01
-0.04
-1.31%
Sophia Genetics Sa stock is traded at $3.05, with a volume of 28,813.
It is up +1.67% in the last 24 hours and down -2.87% over the past month.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
See More
Previous Close:
$3.00
Open:
$3.02
24h Volume:
28,813
Relative Volume:
0.92
Market Cap:
$203.83M
Revenue:
$64.49M
Net Income/Loss:
$-71.40M
P/E Ratio:
-2.7982
EPS:
-1.09
Net Cash Flow:
$-52.00M
1W Performance:
+6.27%
1M Performance:
-2.87%
6M Performance:
-8.68%
1Y Performance:
-40.89%
1-Day Range:
$3.01
$3.16
1-Week Range:
$2.8511
$3.19
52-Week Range:
$2.58
$5.22
Sophia Genetics Sa Stock (SOPH) Company Profile
Name
Sophia Genetics Sa
Sector
Industry
Phone
-
Address
-
Compare SOPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SOPH
Sophia Genetics Sa
|
3.05 | 191.78M | 64.49M | -71.40M | -52.00M | -1.09 |
|
VEEV
Veeva Systems Inc
|
289.94 | 45.60B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
58.66 | 9.42B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
112.70 | 8.73B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
57.34 | 9.76B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
40.09 | 6.67B | 906.14M | -52.62M | 89.62M | -0.3621 |
Sophia Genetics Sa Stock (SOPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Craig Hallum | Buy |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-03-23 | Initiated | BTIG Research | Buy |
| Nov-23-22 | Initiated | Credit Suisse | Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-17-21 | Initiated | Cowen | Outperform |
| Aug-17-21 | Initiated | Credit Suisse | Outperform |
| Aug-17-21 | Initiated | JP Morgan | Overweight |
| Aug-17-21 | Initiated | Morgan Stanley | Overweight |
View All
Sophia Genetics Sa Stock (SOPH) Latest News
Millennium Management LLC Increases Position in SOPHiA GENETICS SA (NASDAQ:SOPH) - Defense World
Dimensional Fund Advisors LP Has $68,000 Stock Holdings in SOPHiA GENETICS SA (NASDAQ:SOPH) - Defense World
SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2025 Earnings Call Transcript - Insider Monkey
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates - MSN
SOPHiA GENETICS Q1 2025 Earnings Call Highlights - TipRanks
SOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
SOPHiA GENETICS SA 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SOPH) - Seeking Alpha
SOPHiA GENETICS sets date for annual shareholder meeting - Investing.com Australia
SOPHiA GENETICS sets date for annual shareholder meeting By Investing.com - Investing.com South Africa
Sophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ... By GuruFocus - Investing.com Canada
SOPHiA GENETICS Reports Strong Q1 2025 Growth - TipRanks
SOPHiA GENETICS Q1 2025 Earnings Call Transcript - MarketBeat
SOPHiA GENETICS Reports Q1 2025 Financial Results - TipRanks
SOPH Hits Revenue and Margin Milestones in Q1 2024 | SOPH Stock News - GuruFocus
SOPHiA GENETICS Reports First Quarter 2025 Results - Quantisnow
Earnings To Watch: Sophia Genetics SA (SOPH) Reports Q1 2025 Result - Yahoo Finance
Sophia Genetics SA expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Promising Penny Stocks To Consider In April 2025 - simplywall.st
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? - The Globe and Mail
SOPHia Genetics expands testing partnership with AstraZeneca - MSN
SOPHiA Genetics (SOPH) Expands Liquid Biopsy Collaboration with AstraZeneca - GuruFocus
SOPHiA GENETICS Expands Global Collaboration With AstraZeneca To Advance Liquid Biopsy Testing - Nasdaq
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR – Company AnnouncementFT.com - Financial Times
SOPHiA GENETICS SA's (NASDAQ:SOPH) market cap touched US$204m last week, benefiting both individual investors who own 51% as well as institutions - simplywall.st
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS - Yahoo Finance
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025 - marketscreener.com
SOPHiA GENETICS Q1 2025 Earnings: AI Healthcare Leader Reports Financial Results May 6 - Stock Titan
SOPHiA GENETICS (SOPH) Forecasts Revenue Growth Despite Volatili - GuruFocus
SOPHiA GENETICS (SOPH) Forecasts Revenue Growth Despite Volatility - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM Platform and its Liquid Biopsy Capabilities - MarketScreener
SOPHiA GENETICS Partners With Precision for Medicine - marketscreener.com
Major AI Breakthrough: SOPHiA GENETICS Partners to Transform Clinical Trial Analysis - Stock Titan
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities - MarketScreener
Precision Medicine Software Market: Global Expansion & Growth - openPR.com
AI In Genomics Market 2030: The $1 Billion Race Between IBM, NVIDIA & Illumina - blog.libero.it
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? - Yahoo Finance
Mesoblast (NASDAQ:MESO) & SOPHiA GENETICS (NASDAQ:SOPH) Financial Review - Defense World
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
With A 25% Price Drop For SOPHiA GENETICS SA (NASDAQ:SOPH) You'll Still Get What You Pay For - Simply Wall St
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC - Barchart
Tempus AI Surges 40% YTD: Are New Strategic Deals A Buy Signal? - Barchart.com
Two Use Cases for AI in Healthcare - Streetwise Reports
March 2025's Promising Penny Stocks To Consider - Simply Wall St
Blood Cancer Diagnostics Market Analysis Report 2025-2030, with Quest Diagnostics, Illumina, InVivoScribe, Asuragen, Danaher, Sequenta, SkylineDx, Bio-Rad Laboratories, Alercell & Sophia Genetics - Yahoo Finance
Precision Medicine Software Market Set for Global Expansion - openPR.com
Sophia Genetics at TD Cowen Conference: AI-Powered Growth Strategy By Investing.com - Investing.com UK
SOPHiA GENETICS : To Present at the NVIDIA GTC AI Conference -March 06, 2025 at 05:30 am EST - Marketscreener.com
BTIG cuts Sophia Genetics stock price target to $5, maintains buy - Investing.com
SOPHiA GENETICS Full Year 2024 Earnings: In Line With Expectations - Yahoo Finance
Sophia Genetics Sa Stock (SOPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.22%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):